ANURAS2025-04-012025-06-30ANURAS2025-06-30ANURAS2025-04-012025-06-30in-capmkt:OtherExpenses1MemberANURAS2025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1ANURAS2025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss2ANURAS2025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1ANURAS2025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss2ANURAS2025-06-30Statement1ANURAS2025-04-012025-06-30Statement1ANURAS2025-06-30StatementDynamic1I1Statement1ANURAS2025-06-30StatementDynamic1I2Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares543275ANURASNOTLISTEDINE930P01018ANUPAM RASAYAN INDIA LIMITEDMain BoardEquity2025-04-012026-03-312025-08-132025-08-08INRMillionsQuarterlyFirst quarterSingle segmentManufacturing of Industrial Chemicals2025-08-1317:34:002025-08-1317:58:00Not applicabletrue1falseNot applicable as there is no default.2025-04-012025-06-30UnauditedStandalone315694000048260000320520000025731900000-11617000001231500003372200002643700006797600002815990000389210000038921000068120000241500009227000002969400000000296940000-84400002885000001099310000102.72.7002.72.71 The above Standalone financial results for the quarter ended June 30 2025 have been prepared by the Company in accordance with Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended and were reviewed by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on August 13 2025. <BR> 2 Based on the management approach as defined in Ind AS 108 Operating Segments the Chief Operating Decision Maker CODM evaluates the companys performance and allocates resources based on an analysis of various performance indicators of the business segments in which the company operates. The Company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals which the management and CODM recognise as the sole business segment. Hence disclosure of segment wise information is not required and accordingly not provided. <BR> 3 Subsequent to the quarter end the Company has declared and paid an interim dividend for Financial Year 2024 25 of INR 0.75 Rupees per equity share of face value of INR 10 Rupees each. <BR> 4 The figures of the previous period have been re grouped rearranged and or recasted wherever considered necessary. The figures of the last quarter as reported are the balancing figures between audited figures in respect of the full financial year ended March 31 2025 and the published unaudited year to date figures up to third quarter of the previous financial year end and the figures upto the end of the third quarter had only been reviewed and not subject to audit. Other Expenses679760000Gain/(loss) on remeasurements of the defined benefits plan-17630000Income Tax (expense)/Income on remeasurements of the defined benefits plan6160000-114700000Effective portion of Gain/(Loss) on hedging instruments in a cash flow hedge4660000Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge-163000030300000-8440000Preferential Issues2023-12-0655000000002025-06-30trueCRISIL Ratings LimitedfalseNANANAAshish GuptaCompany Secretary and Compliance OfficerSurat2025-08-13Part or full repayment of LoansNA4296900000025468800000Notes <br></br> <br></br> 1 As the date of allotment of both the securities i.e. equity shares and warrants are different we have mentioned the date of Extraordinary General Meeting i.e. December 06 2023 as the Date of raising funds in the above table which happens to be the date of approval of members for raising the funds by way of issue of equity shares and warrants under Preferential Issue. <br></br> <br></br> 2. Total issue size of Preferential Issue is mentioned in the column Amount Raised out of which <br></br> <br></br> i Rs. 180 Crores have been received as the allotment money against 1904540 equity shares issued at Rs. 945.11 per share allotted on December 19 2023. <br></br> <br></br> ii Rs. 92.50 Crores have been received towards 25 percent upfront amount against 3914886 warrants allotted on January 23 2024 which were convertible into equal number of equity shares. <br></br> <br></br> iii Remaining 75 percent amount i.e. Rs. 277.50 Crores against the aforesaid warrants was received after the end of the reporting quarter upon conversion of warrants into equity shares. Accordingly the report on the utilization of the said funds will be reported in the next quarter.General Corporate PurposesNA120310000001781200000Notes <br></br> <br></br> 1 As the date of allotment of both the securities i.e. equity shares and warrants are different we have mentioned the date of Extraordinary General Meeting i.e. December 06 2023 as the Date of raising funds in the above table which happens to be the date of approval of members for raising the funds by way of issue of equity shares and warrants under Preferential Issue. <br></br> <br></br> 2. Total issue size of Preferential Issue is mentioned in the column Amount Raised out of which <br></br> <br></br> i Rs. 180 Crores have been received as the allotment money against 1904540 equity shares issued at Rs. 945.11 per share allotted on December 19 2023. <br></br> <br></br> ii Rs. 92.50 Crores have been received towards 25 percent upfront amount against 3914886 warrants allotted on January 23 2024 which were convertible into equal number of equity shares. <br></br> <br></br> iii Remaining 75 percent amount i.e. Rs. 277.50 Crores against the aforesaid warrants was received after the end of the reporting quarter upon conversion of warrants into equity shares. Accordingly the report on the utilization of the said funds will be reported in the next quarter.